172 related articles for article (PubMed ID: 34229620)
21. Seizures as a complication of recreational drug use: Analysis of the Euro-DEN Plus data-set.
Wolfe CE; Wood DM; Dines A; Whatley BP; Yates C; Heyerdahl F; Hovda KE; Giraudon I; Dargan PI;
Neurotoxicology; 2019 Jul; 73():183-187. PubMed ID: 30974132
[TBL] [Abstract][Full Text] [Related]
22. Synthetic Cannabinoids.
Mills B; Yepes A; Nugent K
Am J Med Sci; 2015 Jul; 350(1):59-62. PubMed ID: 26132518
[TBL] [Abstract][Full Text] [Related]
23. Perfusion Index Analysis in Patients Presenting to the Emergency Department Due to Synthetic Cannabinoid Use.
Yeniocak S
Medicina (Kaunas); 2019 Nov; 55(12):. PubMed ID: 31756995
[No Abstract] [Full Text] [Related]
24. Pre-hospital identification and post-recovery challenges of intoxication with synthetic cannabinoid containing legal high products such as 'Exodus Damnation'.
Fitzpatrick D; O'Meara P; Cunningham A
Scott Med J; 2016 Nov; 61(4):192-194. PubMed ID: 27688259
[TBL] [Abstract][Full Text] [Related]
25. Cannabis and synthetic cannabinoid exposure reported to the Israel poison information center: Examining differences in exposures to medical and recreational compounds.
Sznitman SR; Pinsky-Talbi L; Salameh M; Moed T; Bentur Y
Int J Drug Policy; 2020 Mar; 77():102711. PubMed ID: 32126489
[TBL] [Abstract][Full Text] [Related]
26. The Relevance of Sex in the Association of Synthetic Cannabinoid Use With Psychosis and Agitation in an Inpatient Population.
Bassir Nia A; Mann CL; Spriggs S; DeFrancisco DR; Carbonaro S; Parvez L; Galynker II; Perkel CA; Hurd YL
J Clin Psychiatry; 2019 Jul; 80(4):. PubMed ID: 31265768
[TBL] [Abstract][Full Text] [Related]
27. Clinical Characteristics of Synthetic Cannabinoid Use in a Large Urban Psychiatric Emergency Setting.
Manseau MW; Rajparia A; Joseph A; Azarchi S; Goff D; Satodiya R; Lewis CF
Subst Use Misuse; 2017 May; 52(6):822-825. PubMed ID: 28156305
[TBL] [Abstract][Full Text] [Related]
28. Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings.
Hermanns-Clausen M; Kneisel S; Szabo B; Auwärter V
Addiction; 2013 Mar; 108(3):534-44. PubMed ID: 22971158
[TBL] [Abstract][Full Text] [Related]
29. Characteristics of Synthetic Cannabinoid and Cannabis Users Admitted to a Psychiatric Hospital: A Comparative Study.
Shalit N; Barzilay R; Shoval G; Shlosberg D; Mor N; Zweigenhaft N; Weizman A; Krivoy A
J Clin Psychiatry; 2016 Aug; 77(8):e989-95. PubMed ID: 27379411
[TBL] [Abstract][Full Text] [Related]
30. Synthetic Cannabinoid Use in a Psychiatric Patient Population: A Pilot Study.
Welter S; Lücke C; Lam AP; Custal C; Moeller S; Sörös P; Thiel CM; Philipsen A; Müller HHO
Eur Addict Res; 2017; 23(4):182-193. PubMed ID: 28848170
[TBL] [Abstract][Full Text] [Related]
31. Role of cannabis in digestive disorders.
Goyal H; Singla U; Gupta U; May E
Eur J Gastroenterol Hepatol; 2017 Feb; 29(2):135-143. PubMed ID: 27792038
[TBL] [Abstract][Full Text] [Related]
32. Cannabinoids for treating inflammatory bowel diseases: where are we and where do we go?
Hasenoehrl C; Storr M; Schicho R
Expert Rev Gastroenterol Hepatol; 2017 Apr; 11(4):329-337. PubMed ID: 28276820
[TBL] [Abstract][Full Text] [Related]
33. Synthetic cannabinoid intoxication: a case series and review.
Harris CR; Brown A
J Emerg Med; 2013 Feb; 44(2):360-6. PubMed ID: 22989695
[TBL] [Abstract][Full Text] [Related]
34. The Chameleon-Like Properties of Psychoactive Drugs: Examinations with HR LC-MS/MS Technology of Patients Presenting at the Emergency Department Following the Use of Synthetic Cannabinoids: A Case Series and Literature Review.
Altintop I; Karakukcu C
Behav Sci (Basel); 2018 Sep; 8(10):. PubMed ID: 30248995
[TBL] [Abstract][Full Text] [Related]
35. Synthetic cannabinoid "Black Mamba" infidelity in patients presenting for emergency stabilization in Colorado: a P SCAN Cohort.
Brandehoff N; Adams A; McDaniel K; Banister SD; Gerona R; Monte AA
Clin Toxicol (Phila); 2018 Mar; 56(3):193-198. PubMed ID: 28862050
[TBL] [Abstract][Full Text] [Related]
36. Emergency physicians' knowledge of cannabinoid designer drugs.
Lank PM; Pines E; Mycyk MB
West J Emerg Med; 2013 Sep; 14(5):467-70. PubMed ID: 24106544
[TBL] [Abstract][Full Text] [Related]
37. Cannabinoids for fibromyalgia.
Walitt B; Klose P; Fitzcharles MA; Phillips T; Häuser W
Cochrane Database Syst Rev; 2016 Jul; 7(7):CD011694. PubMed ID: 27428009
[TBL] [Abstract][Full Text] [Related]
38. Weeding Out the Problem: The Impact of Preoperative Cannabinoid Use on Pain in the Perioperative Period.
Liu CW; Bhatia A; Buzon-Tan A; Walker S; Ilangomaran D; Kara J; Venkatraghavan L; Prabhu AJ
Anesth Analg; 2019 Sep; 129(3):874-881. PubMed ID: 31425232
[TBL] [Abstract][Full Text] [Related]
39. K2--not the spice of life; synthetic cannabinoids and ST elevation myocardial infarction: a case report.
McKeever RG; Vearrier D; Jacobs D; LaSala G; Okaneku J; Greenberg MI
J Med Toxicol; 2015 Mar; 11(1):129-31. PubMed ID: 25154434
[TBL] [Abstract][Full Text] [Related]
40. Novel psychoactive substances-related presentations to the emergency departments of the European drug emergencies network plus (Euro-DEN plus) over the six-year period 2014-2019.
Crulli B; Dines AM; Blanco G; Giraudon I; Eyer F; Liechti ME; Miró Ò; Hovda KE; Heyerdahl F; Yates C; Vallersnes OM; Wood DM; Dargan PI;
Clin Toxicol (Phila); 2022 Dec; 60(12):1318-1327. PubMed ID: 36322684
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
